首頁 > 市場調查報告書 > 醫療設備

生技設備

市場調查報告書

商品編碼

2055602

胜肽合成市場（第三版）：原料藥與預測至2035年－依原料藥類型、胜肽合成方法類型、化學合成方法類型、業務規模、公司規模與地區分類

Peptide Synthesis Market (3rd Edition): Trends and Forecast Till 2035 - Distribution by Type of API, Type of Peptide Synthesis Method, Type of Chemical Synthesis Method, Scale of Operation, Company Size, and Geographical Regions

出版日期: 2026年06月02日 | 出版商:

Roots Analysis | 英文 390 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

胜肽合成市場概覽

預計到 2035 年，胜肽合成市場將以 4.1% 的年複合成長率成長，從目前的 42 億美元成長到 60 億美元。

胜肽合成市場

市場規模和機會分析是根據以下參數進行細分的：

按 API 類型

非專利API
新化學物質

胜肽合成方法

化學合成
非化學合成

依化學合成方法類型

固相合成
液相合成
混合相合成

按企業規模

商業規模
臨床前/臨床規模

按公司規模

小規模企業
中型公司
大型企業和巨型企業

按地區

北美洲
美國
加拿大
歐洲
比利時
瑞士
英國
德國
愛爾蘭
荷蘭
義大利
法國
瑞典
其他歐洲國家

亞太地區及世界其他地區

中國
印度
日本
韓國
亞太地區其他國家

胜肽合成市場：成長與趨勢

近年來，由於胜肽類藥物具有代謝穩定性高、對生物標的特異性強、親和性優點，其作為治療候選藥物的重要性日益凸顯。在此期間，受肽類治療方法需求成長的推動，胜肽類藥物生產領域取得了顯著進展。目前，全球監管機構已核准約100種胜肽類藥物用於治療多種慢性疾病，包括癌症、慢性疼痛、糖尿病、HIV感染疾病、多發性硬化症和骨質疏鬆症。該領域研究活動的活性化和對這些治療方案需求的持續成長，促使研發人員不斷提升自身能力並改善生產系統。然而，胜肽類藥物合成過程面臨許多挑戰，例如產能不足。因此，研發人員擴大將複雜的生產作業外包給專業的合約服務供應商，從而降低成本並加快產品上市速度。

成長要素－市場擴張的策略促進因素

受肽類藥物、診斷試劑和研究工具需求的推動，肽合成市場正經歷強勁成長和技術突破。關鍵進展包括自動化、人工智慧整合和環保化學技術，從而提高了效率和擴充性。此外，癌症和代謝紊亂等慢性疾病在全球範圍內的日益普遍，也推動了對更具標靶性和療效的胜肽類治療方法的需求成長。這種不斷成長的治療需求促使開發平臺規模更大、更複雜，導致製藥公司將臨床和商業供應所需的原料藥生產外包給專業的合約研發生產機構（CDMO）。

市場挑戰－阻礙進展的主要障礙

儘管治療和研究應用領域的需求強勁，但肽合成市場仍面臨許多挑戰，阻礙其成長。主要挑戰包括高昂的生產成本、規模化生產難題以及嚴格的監管，這些挑戰對中小企業和複雜胜肽的開發影響尤其顯著。此外，嚴格的GMP/ICH合規性、驗證和品管流程延長了開發週期，推高了成本，並為新進入者設定了准入障礙。免疫抗原性風險需要進行廣泛的測試和設計重新調整，而不永續的溶劑和廢棄物，以及供應鏈的脆弱性，使得更環保的製程轉型變得困難重重。

胜肽合成市場—關鍵洞察

本報告詳細分析了胜肽合成市場的現狀，並指出了該行業的潛在成長機會。報告的主要發現包括：

目前全球約有 95 家公司聲稱有能力提供胜肽原料藥的契約製造。

該領域近 70% 的公司提供非專利原料藥的契約製造服務，約 20% 的公司聲稱具備使用所有三種化學合成方法生產胜肽的必要能力。
在該行業達成的交易中，超過 35% 為收購，而歐洲大陸的大部分交易都是由總部位於歐洲的公司達成的。
隨著對胜肽類藥物的需求加速成長，各公司正在進行策略性投資，以擴大生產能力並加強其技術能力，這一趨勢在亞太地區最為明顯。

針對各種胜肽類療法的臨床試驗廣泛分佈於多個地區。北美地區的患者入組人數最多，共有 86,608 名參與者。
為滿足日益成長的胜肽類藥物需求，各公司正積極努力提高產能。臨床試驗數量的增加也清楚地表明，研發人員對胜肽類藥物的興趣日益濃厚。
隨著胜肽類原料藥的複雜性日益增加，外包需求也隨之激增。預計到2035年，這一數字將超過4,400公斤，其中包括臨床和商業規模。
全球胜肽類原料藥契約製造運作較為分散。值得注意的是，超過90%的總產能集中在大型和超大型企業擁有的工廠。
預計多家胜肽類藥物研發公司將與胜肽類原料藥契約製造服務供應商建立策略合作夥伴關係，以外包複雜的生產流程。
雖然各國為胜肽類原料藥生產所製定的法律規範各不相同，但它們都具有通用的目標：保護公眾健康、確保產品品質和最大限度地降低相關風險。
受慢性疾病日益普遍（需要新的個人化治療）以及基於胜肽的療法的持續研究的推動，預計該市場將穩步擴張。
預計固相合成收入將佔市場佔有率的近 50%，而中小企業胜肽類原料藥契約製造市場預計將以更快的速度成長。

受慢性病盛行率上升以及胜肽類原料藥外包給專業合約生產商 (CMO) 的趨勢推動，美國胜肽類原料藥契約製造市場預計將穩定成長。
由於強大的製藥生產基礎和有利的法規環境，預計到 2035 年，美國肽類原料藥契約製造市場將達到 18 億美元。

胜肽合成市場：主要細分市場

固相合成是胜肽合成的基礎。

從化學合成方法類型來看，全球市場可分為固相合成、液相合成及混合相合成。根據胜肽合成市場報告，今年固相合成佔了49%的市場。其主導地位主要歸功於固相合成的諸多優勢，例如線性胜肽的快速生產和易於純化，以及成本優勢。值得注意的是，混合相合成預計將呈現更高的年複合成長率。這一成長主要源自於此方法特別適用於研發管線中複雜且長的胜肽序列。此方法融合了固相胜肽合成（SPPS）和液相胜肽合成（LPPS）的優勢，為難以以單一技術生產的新一代治療藥物提供了最佳的效率、產率和成本效益。

商業規模的生產製造佔據了主導市場佔有率。

從業務規模角度來看，全球市場可分為商業規模和臨床前/臨床規模。據預測，在胜肽合成市場中，商業規模部分佔總市佔率的90%以上。值得注意的是，商業規模部分預計將保持主導地位，並以更高的年複合成長率成長。胜肽合成市場規模龐大的主要原因是GMP級胜肽原料藥（API）生產具有高產量和高經濟價值。與臨床前和臨床規模項目相比，已上市治療藥物的長期供應合約創造了產生收入機會。

肽合成市場由歐洲主導。

我們的胜肽合成市場分析顯示，歐洲市場佔據主導地位，佔總收入的40%。這一主導地位歸功於全球大部分生產能力集中在該地區、該地區開展的臨床試驗數量不斷增加，以及由強大的產學研合作支持的穩健創新生態系統。

第一次調查總結

本市場報告中提出的觀點和見解也受到與主要產業相關人員討論的影響。本市場報告包含與以下相關人員的詳細訪談記錄：

德國小型企業創辦人兼所有者
德國中小企業財務總監
美國、中小企業、首席商務官
美國小型企業、科學營運與技術行銷資深總監
愛爾蘭一家大型公司的胜肽類副總裁
日本某大型企業高階經理人、胜肽業務專案負責人
印度中小企業首席科學長兼聯合創辦人

肽合成市場主要公司範例

AmbioPharm
Creative Peptides
CSBio
Bachem
BCN Peptides
CordenPharma
PolyPeptide
Senn Chemicals
Auspep
Hybio Pharmaceuticals
Peptide Institute
ScinoPharm

胜肽合成市場：研究範圍

市場規模和機會分析：本報告對肽合成市場進行了詳細分析，重點關注關鍵市場細分，例如 [A] API 類型、[B] 肽合成方法類型、[C] 化學合成方法類型、[D] 業務規模、[E] 公司規模和 [F] 地區。
市場概覽：本部分詳細概述了為肽類藥物提供合約原料藥生產服務的契約製造的當前市場狀況，以及以下資訊：[A] 成立年份，[B] 作為肽類原料藥契約製造的經驗年限，[C] 公司規模，[D] 總部所在地，[E] 產品類型，[F] 生產的原料藥，[G] 業務規模的合成類型，化學胜肽合成方法類型，[K] 提供的胜肽修飾類型，[L] 採用的純化技術類型，[M] 監管認證和批准，[N] 地理分佈，以及 [O] 肽類原料藥生產設施的位置。
企業競爭分析：這是一項對肽類原料藥契約製造製造業的主要契約製造製造商進行的深入競爭分析，基於幾個相關參數，例如[A]供應商實力、[B]服務組合和[A]提供的胜肽修飾服務數量。
公司簡介：我們根據[A]成立年份、[B]總部所在地、[C]產品系列、[D]近期發展和[E]未來展望，提供北美、歐洲和亞太地區胜肽類藥物製造市場領先公司的詳細簡介。
近期趨勢：本報告分析了胜肽類原料藥契約製造產業中契約製造的最新趨勢和舉措。報告重點介紹了過去五年中達成的多項合作、聯合研究項目和業務拓展計劃。
臨床試驗分析：[A] 試驗註冊年份，[B] 註冊患者人數，[C] 患者性別，[D] 試驗階段，[E]實驗狀況，[F] 治療領域，[G] 申辦方/共同研究者類型，[H] 試驗設計，[I] 最活躍的公司（基於臨床試驗數量），以及[H] 地區。
區域產能分析：[A] CMO 數量，[B] 臨床試驗點數量，[C] 臨床試驗數量，[D] 入組患者數量，[E] 肽類生產設施數量，[F] 產品類型，[G] 進行臨床和商業生產的 CMO 數量，[H] 對肽類藥物的需求，以及 [I] 設備。
需求分析：我們根據相關參數（如[A]目標患者數量、[B]給藥頻率和[C]劑量）對肽類藥物的年度商業和臨床需求進行詳細分析。
產能分析：這是對全球胜肽原料藥契約製造市場契約製造生產商已安裝產能的估算。此估算考慮了可用胜肽產能按以下因素的分佈：[A] 公司規模，[B] 業務規模，以及 [C] 生產設施位置。
潛在合作夥伴分析：本分析根據與胜肽類藥物開發公司合作的可能性，對潛在策略夥伴進行分類和介紹。
內部生產與外包的決策架構：本定性分析闡明了胜肽類藥物開發公司在決定是自行生產產品還是利用 CMO（合約生產組織）的服務時應考慮的各種因素。
總擁有成本 (TCO)：這是對胜肽類契約製造服務供應商的總擁有成本的詳細分析。它基於證據，估算了 20 年期間的直接成本和間接成本，並考慮了 10 個相關參數。
SWOT分析：本分析基於SWOT框架，探討了可能影響該領域發展的產業相關趨勢、關鍵促進因素和挑戰。其中包括哈維鮑爾分析，重點闡述了每個SWOT參數對產業趨勢的相對影響。

章節概要
總部位於北美的原料藥契約製造
- AmbioPharm
- Creative Peptides
- CSBio
歐洲原料藥契約製造
- Bachem
- BCN Peptides
- CordenPharma
- PolyPeptide
- Senn Chemicals
總部位於亞太地區的原料藥契約製造生產商。
- Auspep
- Hybio Pharmaceutical
- Peptide Institute
- ScinoPharm
胜肽原料藥契約製造製造商
- Amneal Pharmaceuticals
- Asymchem
- Aurisco Pharma
- Dr Reddy's Laboratories
- Hybio Pharmaceutical
- JYMed Peptide
- Neuland Labs
- Sinopep-Allsino Biopharmaceutical
- SK Pharmteco
- WuXi STA（a WuXi AppTec company）

第11章近期趨勢

章節概要
夥伴關係與合作
近期擴張
新型胜肽合成技術

第12章：臨床試驗分析

章節概要
研究範圍和調查方法
胜肽類藥物：臨床試驗分析

第13章區域能力分析

章節概要
關鍵假設和調查方法
胜肽類原料藥契約製造設施整體情況
北美胜肽類原料藥的契約製造
歐洲胜肽類原料藥的契約製造
在亞太地區及其他地區提供胜肽類原料藥的契約製造。

第14章需求分析

第15章能力分析

第16章：潛在合作夥伴分析

第17章：製造與採購之間的決策架構

第18章胜肽類契約製造組織的總擁有成本

第19章：全球胜肽原料藥契約製造市場

第20章：胜肽類原料藥契約製造市場（依原始藥物類型分類）

第21章：胜肽類原料藥契約製造市場（依胜肽合成方法分類）

第22章：胜肽類原料藥契約製造市場（依化學合成法）

第23章：胜肽類原料藥契約製造市場（依企業規模分類）

第24章：胜肽類原料藥契約製造市場（依公司規模分類）

第25章：胜肽類原料藥契約製造市場（按地區分類）

區域市場機會分析

第26章市場機會分析：北美

第27章市場機會分析：歐洲

第28章市場機會分析：亞太地區及世界其他地區

第29章 SWOT分析

第30章：ROOTS的策略建議

第31章來自初步調查的見解

第32章：報告結論

第33章：表格形式數據

第34章公司與組織列表

第35章客製化的機會

第36章：ROOTS訂閱服務

簡介目錄圖表

Product Code: RA100326

Peptide Synthesis Market: Overview

As per Roots Analysis, the peptide synthesis market is estimated to grow from USD 4.2 billion in the current year to USD 6.0 billion by 2035, at a CAGR of 4.1% during the forecast period, till 2035.

Peptide Synthesis Market

The market sizing and opportunity analysis has been segmented across the following parameters:

By Type of API

Generic APIs
New Chemical Entities

By Type of Peptide Synthesis Method

Chemical Synthesis
Non-Chemical Synthesis

By Type of Chemical Synthesis Method

Solid Phase Synthesis
Liquid Phase Synthesis
Hybrid Phase Synthesis

By Scale of Operation

Commercial Scale
Preclinical / Clinical Scale

By Company Size

Small Companies
Mid-sized Companies
Large and Very Large Companies

By Geographical Regions

North America
US
Canada
Europe
Belgium
Switzerland
UK
Germany
Ireland
Netherlands
Italy
France
Sweden
Rest of Europe

Asia-Pacific and Rest of the World

China
India
Japan
Korea
Rest of Asia-Pacific and Other Countries

Peptide Synthesis Market: Growth and Trends

Over the years, peptides have gained significance as therapeutic candidates due to their improved metabolic stability, specificity for biological targets, and greater affinity. In this time frame, the peptide production field has advanced considerably with the increasing demand for peptide-based therapies. At present, regulatory bodies in various parts of the world have authorized approximately 100 peptide therapeutics to address a wide range of chronic conditions, such as cancer, chronic pain, diabetes, HIV infection, multiple sclerosis, and osteoporosis. The increasing research efforts in this area and rising demand for such therapeutic options have led developers to enhance their capabilities and improve the production machinery. Nonetheless, the peptide synthesis process faces numerous challenges, such as a lack of production capacity. Consequently, developers are progressively delegating intricate manufacturing tasks to expert contract service providers, allowing for cost savings and quicker market entry

Growth Drivers: Strategic Enablers of Market Expansion

The peptide synthesis market has experienced robust growth and technological breakthroughs, driven by demand for peptide-based therapeutics, diagnostics, and research tools. Key advancements include automation, AI integration, and greener chemistry, enhancing efficiency and scalability. Further, the increasing global prevalence of chronic diseases, such as cancer and metabolic disorders, has intensified the demand for more targeted and effective peptide-based therapies. This growing therapeutic need fuels a larger and more complex R&D pipeline, resulting in drug developers outsourcing API production to specialized CDMOs for clinical and commercial supply.

Market Challenges: Critical Barriers Impeding Progress

The peptide synthesis market faces significant hurdles that hinder its growth despite strong demand for therapeutics and research applications. Key challenges include high production costs, scalability issues, and stringent regulations, which particularly impact smaller players and complex peptide development. Further, stringent GMP / ICH compliance, validation, and quality controls prolong timelines and raise costs, posing entry barriers for new entrants. Immunogenicity risks require extensive testing and redesigns, while unsustainable solvents and waste challenge greener processes amid supply chain vulnerabilities.

Peptide Synthesis Market: Key Insights

The report delves into the current state of the peptide synthesis market and identifies potential growth opportunities within industry. Some key findings from the report include:

The current market landscape features a presence of around 95 companies that claim to have the required capabilities to offer contract manufacturing for peptide APIs, worldwide.

Close to 70% players engaged in this domain offer contract manufacturing services for generic APIs; further, ~20% claim to have the required capabilities to manufacture peptides using all three chemical synthesis methods.
Over 35% of the deals inked in this domain were acquisitions; majority of the intracontinental deals were signed by players based in Europe.
As demand for peptide therapeutics accelerates, companies are strategically investing to scale-up capacity and strengthen their capabilities; this trend is most prominently observed across Asia-Pacific region.

Clinical trials investigating various peptide therapeutics are well distributed across several geographical regions; maximum patient enrollment (with 86,608 patients) was observed in North America.
Players are actively making efforts to increase their production capacities to meet the growing demand for peptide-based drugs; the rising interest of developers in peptides is evident from the increase in clinical studies.
Given the growing complexity of peptide APIs, the demand for outsourcing has upsurged; by 2035, it is anticipated to reach over 4,400 kilograms, across clinical and commercial scales.
The global, installed peptide API contract manufacturing capacity is spread across various geographies; interestingly, over 90% of the total capacity is installed at the facilities owned by large and very large players.
Various peptide therapeutic developers are anticipated to forge strategic alliances with peptide API contract manufacturing service providers in order to outsource complex manufacturing operations.
The regulatory frameworks established for peptide API manufacturing vary across countries, upholding a common goal of protecting public health, ensuring product quality, and minimizing associated risks.
Driven by the increasing number of chronic indications (requiring novel personalized therapies), and ongoing research on peptide-based therapeutics, this market is anticipated to grow at a steady rate.
Close to 50% of the market is anticipated to be captured by revenues generated from solid phase synthesis; the peptide API contract manufacturing market for small companies is likely to grow at a faster pace.

The US peptide API contract manufacturing market is projected to grow at a decent pace, driven by rising prevalence of chronic diseases and increasing peptide API outsourcing to specialized CMOs.
The US peptide API contract manufacturing market, supported by a robust pharmaceutical manufacturing base and a favorable regulatory environment, is projected to reach USD 1.8 billion by 2035.

Peptide Synthesis Market: Key Segments

Solid Phase Synthesis to be the Cornerstone of Peptide Synthesis

In terms of the type of chemical synthesis method, the global market is segmented into solid phase synthesis, liquid phase synthesis, and hybrid phase synthesis. The peptide synthesis market report indicates that the solid phase synthesis method segment accounts for 49% of the total market share, in the current year. This dominance arises from the many benefits of the solid phase synthesis method, such as fast generation of linear peptides, easier purification, and affordability. It is crucial to emphasize that the hybrid phase synthesis segment is expected to experience a greater CAGR. This expansion is mainly due to its distinct appropriateness for the intricate and lengthy peptide sequences entering the R&D pipeline. This method utilizes the advantages of both SPPS and LPPS, providing the best efficiency, yield, and cost-effectiveness for next-generation therapeutics that are challenging to produce with just one technique.

Commercial Scale Manufacturing to Retain Dominant Share

In terms of the different scales of operation, the global market is segmented into commercial scale, and preclinical / clinical scale. The peptide synthesis market prediction suggests that the commercial scale sector represents more than 90% of the total market share. It is worth highlighting that the commercial scale segment will lead in the future and is expected to expand at a greater CAGR. The significant peptide synthesis market size primarily results from the large volumes and high financial value linked to producing GMP-grade peptide APIs. Long-term supply contracts for marketed therapies create revenue generation opportunities that greatly exceed that of preclinical and clinical scale projects.

Europe Dominates the Market for Peptide Synthesis

Our analysis of the peptide synthesis market indicates that Europe is leading by capturing 40% of the total revenue share. This dominance is probably due to the substantial portion of global manufacturing capacity in the region, an increased number of clinical trials conducted there, and a solid innovation ecosystem supported by strong partnerships between academia and industry.

Primary Research Overview

The opinions and insights presented in the market report were also influenced by discussions held with senior stakeholders in the industry. The market report includes detailed transcripts of interviews conducted with the following individuals:

Founder and Owner, Small Company, Germany
Chief Financial Officer, Small Company, Germany
Chief Business Officer, Small Company, US
Senior Director of Scientific Affairs and Technical Marketing, Small Company, US
Vice President, Peptides, Large Company, Ireland
Senior Manager, Peptide Business Project Leader, Large Company, Japan
Chief Scientific Officer, Co-Founder, Small Company, India

Example Players in Peptide Synthesis Market

AmbioPharm
Creative Peptides
CSBio
Bachem
BCN Peptides
CordenPharma
PolyPeptide
Senn Chemicals
Auspep
Hybio Pharmaceuticals
Peptide Institute
ScinoPharm

Peptide Synthesis Market: Research Coverage

Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the peptide synthesis market, focusing on key market segments, including [A] type of API, [B] type of peptide synthesis method, [C] type of chemical synthesis method, [D] scale of operation, [E] company size, and [F] geographical regions.
Market Landscape: A detailed overview of the current market landscape of contract manufacturers offering peptide therapeutics contract API manufacturing services, along with information on several relevant parameters, such as [A] year of establishment, [B] year of experience of peptide API contract manufacturers, [C] company size, [D] location of headquarters, [E] type of product, [F] type of API manufactured, [G] scale of operation, [H] type of service offered, [I] type of peptide synthesis method, [J] type of chemical peptide synthesis method, [K] type of peptide modification offered, [L] type of purification techniques used, [M] regulatory certifications and accreditations, [N] geographical presence and [O] location of peptide API manufacturing facilities.
Company Competitiveness Analysis: An insightful company competitiveness analysis of prominent contract manufacturers in the peptide API contract manufacturing industry, based on several relevant parameters, such as [A] supplier strength, [B] service portfolio and [A] number of peptide modification services offered.
Company Profiles: In-depth profiles of prominent players North America, Europe and Asia-Pacific that are engaged in the peptide therapeutics manufacturing market based on [A] year of establishment, [B] location of headquarters, [C] product portfolio, [D] recent developments and [E] an informed future outlook.
Recent Developments: An analysis on the recent developments and initiatives undertaken by contract manufacturers within the peptide API contract manufacturing industry, highlighting information on several partnerships and collaborations and expansions initiatives that have been inked during the last five years.
Clinical Trial Analysis: An in-depth analysis of completed and ongoing clinical studies of various peptide therapeutics, based on various relevant parameters, such as [A] trial registration year, [A] number of patients enrolled, [B] patient gender, [C] trial phase, [D] trial status, [E] therapeutic area, [F] type of sponsor / collaborator, [G] study design, [H] most active players (in terms of number of clinical trials), and [I] geography.
Regional Capability Analysis: An analysis of peptide API contract manufacturers capabilities in different regions, based on several relevant parameters, such as [A] number of CMOs, [B] number of clinical sites, [C] number of clinical trials, [D] number of patients enrolled, [E] number of peptide manufacturing facilities, [F] type of product, [G] number of clinical / commercial manufacturing CMOs, [H] demand for peptide therapeutics and [I] installed capacity.
Demand Analysis: A detailed analysis of the annual commercial and clinical demand for peptide therapeutics, based on several relevant parameters, such as [A] target patient population, [B] dosing frequency and [C] dosage strength.
Capacity Analysis: An estimate of the global, installed capacity of contract manufacturers in the peptide API contract manufacturing market, taking into consideration the distribution of available peptide production capacity across [A] companies of different sizes, [B] scale of operation, and [C] location of manufacturing facility.
Likely Partners Analysis: An analysis highlighting potential strategic partners segregated based on the likelihood of entering into collaboration with peptide therapeutics developers.
Make Versus Buy Decision Making Framework: A qualitative analysis highlighting various factors that need to be taken into consideration by peptide drug developers, while deciding whether to manufacture their respective products in-house or engage the services of a CMO.
Total Cost of Ownership: A detailed analysis of the total cost of ownership for a peptide contract manufacturing service provider. It features an informed estimate of direct and indirect expenses taking into consideration 10 relevant parameters, over a span of 20 years.
SWOT Analysis: A discussion on industry affiliated trends, key drivers and challenges, under a SWOT framework, which are likely to impact the evolution of this field; it includes a Harvey ball analysis, highlighting the relative impact of each SWOT parameter on industry dynamics.

Key Questions Answered in this Report

Which are the leading companies in peptide synthesis market?
Which region dominates the peptide synthesis market?
What are the key trends observed in the peptide synthesis market?
What factors are likely to influence the evolution of this market?
What are the primary challenges faced by peptide synthesis manufacturers?
What is the current and future market size?
What is the CAGR of this market?
How is the current and future market opportunity likely to be distributed across key market segments?

Reasons to Buy this Report

The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.
The report can aid businesses in identifying future opportunities in any sector. It also helps in understanding if those opportunities are worth pursuing.
The report helps in identifying customer demand by understanding the needs, preferences, and behavior of the target audience in order to tailor products or services effectively.
The report equips new entrants with requisite information regarding a particular market to help them build successful business strategies.
The report allows for more effective communication with the audience and in building strong business relations.

Additional Benefits

Complementary PPT Insights Pack
Complimentary Excel Data Packs for all Analytical Modules in the Report
15% Free Content Customization
Detailed Report Walkthrough Session with Research Team
Free Updated report if the report is 6-12 months old or older

1. PREFACE

1.1. Introduction
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Report Coverage
1.5. Key Questions Answered
1.6. Chapter Outlines

2. RESEARCH METHODOLOGY

2.1. Chapter Overview
2.2. Research Assumptions
- 2.2.1. Market Landscape and Market Trends
- 2.2.2. Market Forecast and Opportunity Analysis
- 2.2.3. Comparative Analysis
2.3. Database Building
- 2.3.1. Data Collection
- 2.3.2. Data Validation
- 2.3.3. Data Analysis
2.4. Project Methodology
- 2.4.1. Secondary Research
  - 2.4.1.1. Annual Reports
  - 2.4.1.2. Academic Research Papers
  - 2.4.1.3. Company Websites
  - 2.4.1.4. Investor Presentations
  - 2.4.1.5. Regulatory Filings
  - 2.4.1.6. White Papers
  - 2.4.1.7. Industry Publications
  - 2.4.1.8. Conferences and Seminars
  - 2.4.1.9. Government Portals
  - 2.4.1.10. Media and Press Releases
  - 2.4.1.11. Newsletters
  - 2.4.1.12. Industry Databases
  - 2.4.1.13. Roots Proprietary Databases
  - 2.4.1.14. Paid Databases and Sources
  - 2.4.1.15. Social Media Portals
  - 2.4.1.16. Other Secondary Sources
- 2.4.2. Primary Research
  - 2.4.2.1. Types of Primary Research
    - 2.4.2.1.1. Qualitative Research
    - 2.4.2.1.2. Quantitative Research
    - 2.4.2.1.3. Hybrid Approach
  - 2.4.2.2. Advantages of Primary Research
  - 2.4.2.3. Techniques for Primary Research
    - 2.4.2.3.1. Interviews
    - 2.4.2.3.2. Surveys
    - 2.4.2.3.3. Focus Groups
    - 2.4.2.3.4. Observational Research
    - 2.4.2.3.5. Social Media Interactions
  - 2.4.2.4. Key Opinion Leaders Considered in Primary Research
    - 2.4.2.4.1. Company Executives (CXOs)
    - 2.4.2.4.2. Board of Directors
    - 2.4.2.4.3. Company Presidents and Vice Presidents
    - 2.4.2.4.4. Research and Development Heads
    - 2.4.2.4.5. Technical Experts
    - 2.4.2.4.6. Subject Matter Experts
    - 2.4.2.4.7. Scientists
    - 2.4.2.4.8. Doctors and Other Healthcare Providers
  - 2.4.2.5. Ethics and Integrity
    - 2.4.2.5.1. Research Ethics
    - 2.4.2.5.2. Data Integrity
- 2.4.3. Analytical Tools and Databases
2.5. Robust Quality Control

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

3.1. Chapter Overview
3.2. Forecast Methodology
- 3.2.1. Top-down Approach
- 3.2.2. Bottom-up Approach
- 3.2.3. Hybrid Approach
3.3. Market Assessment Framework
- 3.3.1. Total Addressable Market (TAM)
- 3.3.2. Serviceable Addressable Market (SAM)
- 3.3.3. Serviceable Obtainable Market (SOM)
- 3.3.4. Currently Acquired Market (CAM)
3.4. Forecasting Tools and Techniques
- 3.4.1. Qualitative Forecasting
- 3.4.2. Correlation
- 3.4.3. Regression
- 3.4.4. Extrapolation
- 3.4.5. Convergence
- 3.4.6. Sensitivity Analysis
- 3.4.7. Scenario Planning
- 3.4.8. Data Visualization
- 3.4.9. Time Series Analysis
- 3.4.10. Forecast Error Analysis
3.5. Key Considerations
- 3.5.1. Demographics
- 3.5.2. Government Regulations
- 3.5.3. Reimbursement Scenarios
- 3.5.4. Market Access
- 3.5.5. Supply Chain
- 3.5.6. Industry Consolidation
- 3.5.7. Pandemic / Unforeseen Disruptions Impact
3.6. Limitations

4. MACRO-ECONOMIC INDICATORS

4.1. Chapter Overview
4.2. Market Dynamics
- 4.2.1. Time Period
  - 4.2.1.1. Historical Trends
  - 4.2.1.2. Current and Forecasted Estimates
- 4.2.2. Currency Coverage
  - 4.2.2.1. Major Currencies Affecting the Market
  - 4.2.2.2. Factors Affecting Currency Fluctuations
  - 4.2.2.3. Impact of Currency Fluctuations on the Industry
- 4.2.3. Foreign Currency Exchange Rate
  - 4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
  - 4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
- 4.2.4. Recession
  - 4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
  - 4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt
- 4.2.5. Inflation
  - 4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
  - 4.2.5.2. Potential Impact of Inflation on the Market Evolution
- 4.2.6. Interest Rates
  - 4.2.6.1. Interest Rates and Their Impact on the Market
  - 4.2.6.2. Strategies for Managing Interest Rate Risk
- 4.2.7. Commodity Flow Analysis
  - 4.2.7.1. Type of Commodity
  - 4.2.7.2. Origins and Destinations
  - 4.2.7.3. Value and Weights
  - 4.2.7.4. Modes of Transportation
- 4.2.8. Global Trade Dynamics
  - 4.2.8.1. Import Scenario
  - 4.2.8.2. Export Scenario
  - 4.2.8.3. Trade Policies
  - 4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
  - 4.2.8.5. Impact of Trade Barriers on the Market
- 4.2.9. War Impact Analysis
  - 4.2.9.1. Russian-Ukraine War
  - 4.2.9.2. Israel-Hamas War
- 4.2.10. COVID Impact / Related Factors
  - 4.2.10.1. Global Economic Impact
  - 4.2.10.2. Industry-specific Impact
  - 4.2.10.3. Government Response and Stimulus Measures
  - 4.2.10.4. Future Outlook and Adaptation Strategies
- 4.2.11. Other Indicators
  - 4.2.11.1. Fiscal Policy
  - 4.2.11.2. Consumer Spending
  - 4.2.11.3. Gross Domestic Product (GDP)
  - 4.2.11.4. Employment
  - 4.2.11.5. Taxes
  - 4.2.11.6. Stock Market Performance
  - 4.2.11.7. Cross-Border Dynamics
4.3. Conclusion

5. EXECUTIVE SUMMARY

5.1. Executive Summary: Market Landscape
5.2. Executive Summary: Market Trends
- 5.2.1. Recent Developments
- 5.2.2. Clinical Trial Analysis
- 5.2.3. Demand and Capacity Analysis
- 5.2.4. Total Cost of Ownership
5.3. Executive Summary: Market Forecast and Opportunity Analysis

6. INTRODUCTION

6.1. Chapter Overview
6.2. Overview of Peptides
- 6.2.1. Structural Analysis of Peptides
- 6.2.2. Classification of Peptides
- 6.2.3. Peptide Synthesis
- 6.2.4. Emerging Technologies for Peptide Synthesis
- 6.2.5. Peptide Modification
  - 6.2.5.1. N-terminal Modifications
  - 6.2.5.2. Internal Modifications
  - 6.2.5.3. C-terminal Modifications
  - 6.2.5.4. Other Modifications
- 6.2.6. Peptide Purification
- 6.2.7. Peptide Purity Guidelines
6.3. Overview of Contract Manufacturing
- 6.3.1. Need for Outsourcing in the Peptide Manufacturing Industry
- 6.3.2. General Considerations for Selecting a CMO Partner
- 6.3.3. Advantages of Outsourcing Manufacturing Operations
- 6.3.4. Risks and Challenges Associated with Outsourcing of Peptide API Manufacturing
6.4. Future Perspectives

7. REGULATORY LANDSCAPE

7.1. Chapter Overview
7.2. Regulatory Scenario: North America
- 7.2.1. Scenario in the US
  - 7.2.1.1. Overview
  - 7.2.1.2. General Guidelines for Peptide Manufacturing
7.3. Regulatory Scenario: Europe
- 7.3.1. Scenario in Europe
  - 7.3.1.1. Overview
  - 7.3.1.2. General Guidelines
- 7.3.2. Scenario in the UK
  - 7.3.2.1. Overview
  - 7.3.2.2. General Guidelines for Peptide Manufacturing
7.4. Regulatory Scenario: Asia-Pacific
- 7.4.1. Overview
- 7.4.2. Scenario in Australia
  - 7.4.2.1. General Guidelines for Peptide Manufacturing
- 7.4.3. Scenario in China
  - 7.4.3.1. General Guidelines for Peptide Manufacturing
  - 7.4.3.2. Tax-related Modifications in
- 7.4.4. Scenario in India
  - 7.4.4.1. General Guidelines for Peptide Manufacturing
  - 7.4.4.2. Tax-related Modifications in
- 7.4.5. Scenario in Japan
  - 7.4.5.1. General Guidelines for Peptide Manufacturing
- 7.4.6. Scenario in South Korea
  - 7.4.6.1. General Guidelines for Peptide Manufacturing
7.5. Challenges Associated with Peptide Manufacturing

8. MARKET LANDSCAPE

8.1. Chapter Overview
8.2. Peptide API Contract Manufacturing: Overall Market Landscape
- 8.2.1. Analysis by Year of Establishment
- 8.2.2. Analysis by Year of Experience of Peptide API Contract Manufacturers
- 8.2.3. Analysis by Company Size
- 8.2.4. Analysis by Location of Headquarters
- 8.2.5. Analysis by Type of Product Manufactured
- 8.2.6. Analysis by Type of API Manufactured
- 8.2.7. Analysis by Scale of Operation
- 8.2.8. Analysis by Type of Service Offered
- 8.2.9. Analysis by Type of Peptide Synthesis Method Used
- 8.2.10. Analysis by Type of Peptide Modification Offered
- 8.2.11. Analysis by Type of Purification Technology Used
- 8.2.12. Analysis by Regulatory Certifications and Accreditations
- 8.2.13. Analysis by Geographical Presence
- 8.2.14. Analysis by Location of Peptide API Manufacturing Facilities
8.3. List of Custom Peptide Manufacturers

9. COMPANY COMPETITIVENSS ANALYSIS

9.1. Chapter Overview
9.2. Key Parameters
9.3. Methodology
9.4. Company Competitiveness Analysis
- 9.4.1. Peptide API Contract Manufacturers Headquartered in North America
- 9.4.2. Peptide API Contract Manufacturers Headquartered in Europe
- 9.4.3. Peptide API Contract Manufacturers Headquartered in Asia-Pacific and Rest of the World

10. COMPANY PROFILES: PEPTIDE API CONTRACT MANUFACTURERS

10.1. Chapter Overview
10.2. Peptide API Contract Manufacturers based in North America
- 10.2.1. AmbioPharm
  - 10.2.1.1. Company Overview
  - 10.2.1.2. Peptide Synthesis Service Portfolio
  - 10.2.1.3. Peptide API Manufacturing Facilities and Capabilities
  - 10.2.1.4. Recent Developments and Future Outlook
- 10.2.2. Creative Peptides
  - 10.2.2.1. Company Overview
  - 10.2.2.2. Peptide Synthesis Service Portfolio
  - 10.2.2.3. Peptide API Manufacturing Facilities and Capabilities
  - 10.2.2.4. Recent Developments and Future Outlook
- 10.2.3. CSBio
  - 10.2.3.1. Company Overview
  - 10.2.3.2. Peptide Synthesis Service Portfolio
  - 10.2.3.3. Peptide API Manufacturing Facilities and Capabilities
  - 10.2.3.4. Recent Developments and Future Outlook
10.3. Peptide API Contract Manufacturers based in Europe
- 10.3.1. Bachem
  - 10.3.1.1. Company Overview
  - 10.3.1.2. Financial Information
  - 10.3.1.3. Peptide Synthesis Service Portfolio
  - 10.3.1.4. Peptide API Manufacturing Facilities and Capabilities
  - 10.3.1.5. Recent Developments and Future Outlook
- 10.3.2. BCN Peptides
  - 10.3.2.1. Company Overview
  - 10.3.2.2. Peptide Synthesis Service Portfolio
  - 10.3.2.3. Peptide API Manufacturing Facilities and Capabilities
  - 10.3.2.4. Recent Development and Future Outlook
- 10.3.3. CordenPharma
  - 10.3.3.1. Company Overview
  - 10.3.3.2. Peptide Synthesis Service Portfolio
  - 10.3.3.3. Peptide API Manufacturing Facilities and Capabilities
  - 10.3.3.4. Recent Developments and Future Outlook
- 10.3.4. PolyPeptide
  - 10.3.4.1. Company Overview
  - 10.3.4.2. Financial Information
  - 10.3.4.3. Peptide Synthesis Service Portfolio
  - 10.3.4.4. Peptide API Manufacturing Facilities and Capabilities
  - 10.3.4.5. Recent Developments and Future Outlook
- 10.3.5. Senn Chemicals
  - 10.3.5.1. Company Overview
  - 10.3.5.2. Peptide Synthesis Service Portfolio
  - 10.3.5.3. Peptide API Manufacturing Facilities and Capabilities
  - 10.3.5.4. Recent Developments and Future Outlook
10.4. Peptide API Contract Manufacturers based in Asia-Pacific
- 10.4.1. Auspep
  - 10.4.1.1. Company Overview
  - 10.4.1.2. Peptide Synthesis Service Portfolio
  - 10.4.1.3. Peptide API Manufacturing Facilities and Capabilities
  - 10.4.1.4. Recent Developments and Future Outlook
- 10.4.2. Hybio Pharmaceutical
  - 10.4.2.1. Company Overview
  - 10.4.2.2. Peptide Synthesis Service Portfolio
  - 10.4.2.3. Peptide API Manufacturing Facilities and Capabilities
  - 10.4.2.4. Recent Developments and Future Outlook
- 10.4.3. Peptide Institute
  - 10.4.3.1. Company Overview
  - 10.4.3.2. Peptide Synthesis Service Portfolio
  - 10.4.3.3. Peptide API Manufacturing Facilities and Capabilities
  - 10.4.3.4. Recent Developments and Future Outlook
- 10.4.4. ScinoPharm
  - 10.4.4.1. Company Overview
  - 10.4.4.2. Financial Information
  - 10.4.4.3. Peptide Synthesis Service Portfolio
  - 10.4.4.4. Peptide API Manufacturing Facilities and Capabilities
  - 10.4.4.5. Recent Developments and Future Outlook
10.5. Company Deep Dive: Peptide API Contract Manufacturers
- 10.5.1. Amneal Pharmaceuticals
  - 10.5.1.1. Company Details
  - 10.5.1.2. Financial Details
  - 10.5.1.3. SWOT Analysis
  - 10.5.1.4. Strategic Framework
  - 10.5.1.5. Recent Developments and Future Outlook
- 10.5.2. Asymchem
  - 10.5.2.1. Company Details
  - 10.5.2.2. Peptide Synthesis Service Portfolio
  - 10.5.2.3. Peptide Synthesis Facilities
  - 10.5.2.4. Financial Details
  - 10.5.2.5. SWOT Analysis
  - 10.5.2.6. Strategic Framework
  - 10.5.2.7. Recent Developments and Future Outlook
- 10.5.3. Aurisco Pharma
  - 10.5.3.1. Company Details
  - 10.5.3.2. Peptide Synthesis Facilities
  - 10.5.3.3. Financial Details
  - 10.5.3.4. SWOT Analysis
  - 10.5.3.5. Strategic Framework
  - 10.5.3.6. Recent Developments and Future Outlook
- 10.5.4. Dr Reddy's Laboratories
  - 10.5.4.1. Company Details
  - 10.5.4.2. Peptide Synthesis Service Portfolio
  - 10.5.4.3. Peptide Synthesis Facilities
  - 10.5.4.4. Financial Details
  - 10.5.4.5. SWOT Analysis
  - 10.5.4.6. Strategic Framework
  - 10.5.4.7. Recent Developments and Future Outlook
- 10.5.5. Hybio Pharmaceutical
  - 10.5.5.1. Company Details
  - 10.5.5.2. Peptide Synthesis Service Portfolio
  - 10.5.5.3. Peptide Synthesis Facilities
  - 10.5.5.4. SWOT Analysis
  - 10.5.5.5. Strategic Framework
  - 10.5.5.6. Recent Developments and Future Outlook
- 10.5.6. JYMed Peptide
  - 10.5.6.1. Company Details
  - 10.5.6.2. Peptide Synthesis Service Portfolio
  - 10.5.6.3. Peptide Synthesis Facilities
  - 10.5.6.4. SWOT Analysis
  - 10.5.6.5. Strategic Framework
  - 10.5.6.6. Recent Developments and Future Outlook
- 10.5.7. Neuland Labs
  - 10.5.7.1. Company Details
  - 10.5.7.2. Peptide Synthesis Service Portfolio
  - 10.5.7.3. Peptide Synthesis Facilities
  - 10.5.7.4. Financial Details
  - 10.5.7.5. SWOT Analysis
  - 10.5.7.6. Strategic Framework
  - 10.5.7.7. Recent Developments and Future Outlook
- 10.5.8. Sinopep-Allsino Biopharmaceutical
  - 10.5.8.1. Company Details
  - 10.5.8.2. Peptide Synthesis Service Portfolio
  - 10.5.8.3. Peptide Synthesis Facilities
  - 10.5.8.4. Financial Details
  - 10.5.8.5. SWOT Analysis
  - 10.5.8.6. Strategic Framework
  - 10.5.8.7. Recent Developments and Future Outlook
- 10.5.9. SK Pharmteco
  - 10.5.9.1. Company Details
  - 10.5.9.2. Financial Details
  - 10.5.9.3. SWOT Analysis
  - 10.5.9.4. Strategic Framework
  - 10.5.9.5. Recent Developments and Future Outlook
- 10.5.10. WuXi STA (a WuXi AppTec company)
  - 10.5.10.1. Company Details
  - 10.5.10.2. Peptide Synthesis Service Portfolio
  - 10.5.10.3. Peptide Synthesis Facilities
  - 10.5.10.4. Financial Details
  - 10.5.10.5. SWOT Analysis
  - 10.5.10.6. Strategic Framework
  - 10.5.10.7. Recent Developments and Future Outlook

11. RECENT DEVELOPMENTS

11.1. Chapter Overview
11.2. Partnerships and Collaborations
- 11.2.1. Partnerships Models
- 11.2.2. List of Partnerships and Collaborations
- 11.2.3. Analysis by Year of Partnership
- 11.2.4. Analysis by Type of Partnership
- 11.2.5. Analysis by Year and Type of Partnership
- 11.2.6. Analysis by Company Size and Type of Partnership
- 11.2.7. Analysis by Scale of Operation
- 11.2.8. Analysis by Scale of Operation and Type of Partnership
- 11.2.9. Analysis by Green Chemistry Integration
- 11.2.10. Most Active Players: Analysis by Number of Partnerships
- 11.2.11. Analysis by Geography
  - 11.2.11.1. Intercontinental and Intracontinental Agreements
  - 11.2.11.2. Local and International Agreements
11.3. Recent Expansions
- 11.3.1. Expansion Models
- 11.3.2. List of Recent Expansions
- 11.3.3. Analysis by Year of Expansion
- 11.3.4. Analysis by Type of Expansion
- 11.3.5. Analysis by Year and Type of Expansion
- 11.3.6. Analysis by Location of Expanded Facility (Region)
- 11.3.7. Analysis by Location of Expanded Facility (Country)
- 11.3.8. Recent Expansions: Analysis by Location of Expanded Facility and Type of Expansion
- 11.3.9. Most Active Players: Analysis by Number of Expansions
- 11.3.10. Recent Expansions: Analysis by Geography (Country)
11.4. Emerging Peptide Synthesis Technologies
- 11.4.1. Chemo-Enzymatic Peptide Synthesis Technology
- 11.4.2. Continuous Flow Technology
- 11.4.3. Green Chemistry

12. CLINICAL TRIAL ANALYSIS

12.1. Chapter Overview
12.2. Scope and Methodology
12.3. Peptide Therapeutics: Clinical Trials Analysis
- 12.3.1. Analysis by Trial Registration Year
- 12.3.2. Analysis by Number of Patients Enrolled by Trial Registration Year
- 12.3.3. Analysis by Trial Phase
- 12.3.4. Analysis of Trials by Trial Registration Year and Trial Phase
- 12.3.5. Analysis by Number of Patients Enrolled by Trial Phase
- 12.3.6. Analysis by Trial Status
- 12.3.7. Analysis by Trial Registration Year and Trial Status
- 12.3.8. Analysis by Therapeutic Area
- 12.3.9. Analysis by Patient Gender
- 12.3.10. Analysis by Type of Sponsor / Collaborator
- 12.3.11. Analysis by Study Design
  - 12.3.11.1. Analysis by Type of Allocation
  - 12.3.11.2. Analysis by Type of Masking
  - 12.3.11.3. Analysis by Type of Intervention
  - 12.3.11.4. Analysis by Trial Purpose
- 12.3.12. Leading Industry Players: Analysis by Number of Clinical Trials
- 12.3.13. Analysis by Geography
  - 12.3.13.1. Analysis of Clinical Trials by Geography
  - 12.3.13.2. Analysis of Clinical Trials by Geography and Trial Status
  - 12.3.13.3. Analysis of Patients Enrolled by Geography
  - 12.3.13.4. Analysis of Patients Enrolled by Geography and Trial Status

13. REGIONAL CAPABILITY ANALYSIS

13.1. Chapter Overview
13.2. Key Assumptions and Methodology
13.3. Overall Landscape of Peptide API Contract Manufacturing Facilities
13.4. Peptide API Contract Manufacturing Capability in North America
13.5. Peptide API Contract Manufacturing Capability in Europe
13.6. Peptide API Contract Manufacturing Capability in Asia-Pacific and Rest of the World

14. DEMAND ANALYSIS

14.1. Chapter Overview
14.2. Assumptions and Methodology
14.3. Peptide API Contract Manufacturing: Annual Global Demand
- 14.3.1. Peptide API Contract Manufacturing: Annual Clinical Demand
  - 14.3.1.1. Clinical Demand for Peptide API Contract Manufacturing: Analysis by Phase of Development
- 14.3.2. Peptide API Contract Manufacturing: Annual Commercial Demand
  - 14.3.2.1. Commercial Demand for Peptide API Contract Manufacturing: Analysis by Mechanism of Action
- 14.3.3. Peptide API Contract Manufacturing: Analysis by Type of Peptide Synthesis Method
- 14.3.4. Peptide API Contract Manufacturing: Analysis by Geographical Regions

15. CAPACITY ANALYSIS

15.1. Chapter Overview
15.2. Key Assumptions and Methodology
15.3. Peptide API Contract Manufacturing: Global Installed Capacity
- 15.3.1. Analysis by Company Size
- 15.3.2. Analysis by Scale of Operation
- 15.3.3. Analysis by Geography
  - 15.3.3.1. Analysis of Peptide API Contract Manufacturing Capacity in North America
  - 15.3.3.2. Analysis of Peptide API Contract Manufacturing Capacity in Europe
  - 15.3.3.3. Analysis of Peptide API Contract Manufacturing Capacity in Asia-Pacific and Rest of the World
- 15.3.4. Analysis by Company Size and Location of Manufacturing Facility
- 15.3.5. Analysis by Chemical Synthesis Method Used
15.4. Concluding Remarks

16. LIKELY PARTNERS ANALYSIS

16.1. Chapter Overview
16.2. Assumptions and Key Parameters
16.3. Scope and Methodology
16.4. Potential Strategic Partners for Peptide API Contract Manufacturers in North America
16.5. Potential Strategic Partners for Peptide API Contract Manufacturers in Europe
16.6. Potential Strategic Partners for Peptide API Contract Manufacturers in Asia Pacific and Rest of the World
16.7. Spider-web Analysis: Potential Strategic Partners

17. MAKE VERSUS BUY DECISION MAKING FRAMEWORK

17.1. Chapter Overview
17.2. Assumptions and Parameter Definitions
17.3. Make versus Buy Decision Making Framework
- 17.3.1. Scenario 1
- 17.3.2. Scenario 2
- 17.3.3. Scenario 3
- 17.3.4. Scenario 4
17.4. Concluding Remarks

18. TOTAL COST OF OWNERSHIP FOR PEPTIDE CONTRACT MANUFACTURING ORGANIZATIONS

18.1. Chapter Overview
18.2. Key Parameters
18.3. Assumptions and Methodology
18.4. Total Cost of Ownership for Peptide API Contract Manufacturing Organization, Y0-Y20
18.5. Total Cost of Ownership for Peptide API Contract Manufacturing Organization: Analysis by CAPEX and OPEX, Y0 and Y20
- 18.5.1. Total Cost of Ownership for Peptide API Contract Manufacturing Organization: Analysis by CAPEX, Y0
- 18.5.2. Total Cost of Ownership for Peptide API Contract Manufacturing Organization: Analysis by OPEX, Y1-Y20

19. GLOBAL PEPTIDE API CONTRACT MANUFACTURING MARKET

19.1. Chapter Overview
19.2. Key Assumptions and Methodology
19.3. Global Peptide API Contract Manufacturing Market, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 19.3.1. Scenario Analysis
  - 19.3.1.1. Conservative Scenario
  - 19.3.1.2. Optimistic Scenario
19.4. Key Market Segmentations

20. PEPTIDE API CONTRACT MANUFACTURING MARKET, BY TYPE OF API

20.1. Chapter Overview
20.2. Key Assumptions and Methodology
20.3. Peptide API Contract Manufacturing Market: Distribution by Type of API
- 20.3.1. Peptide API Contract Manufacturing Market for Generic APIs, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 20.3.2. Peptide API Contract Manufacturing Market for New Chemical Entities, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
20.4. Data Triangulation and Validation

21. PEPTIDE API CONTRACT MANUFACTURING MARKET, BY TYPE OF PEPTIDE SYNTHESIS METHOD

21.1. Chapter Overview
21.2. Key Assumptions and Methodology
21.3. Peptide API Contract Manufacturing Market: Distribution by Type of Peptide Synthesis Method
- 21.3.1. Peptide API Contract Manufacturing Market for Chemical Synthesis, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 21.3.2. Peptide API Contract Manufacturing Market for Non-chemical Synthesis, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
21.4. Data Triangulation and Validation

22. PEPTIDE API CONTRACT MANUFACTURING MARKET, BY TYPE OF CHEMICAL SYNTHESIS METHOD

22.1. Chapter Overview
22.2. Key Assumptions and Methodology
22.3. Peptide API Contract Manufacturing Market: Distribution by Type of Chemical Synthesis Method
- 22.3.1. Chemical Synthesis Market for Solid Phase Synthesis, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 22.3.2. Chemical Synthesis Market for Liquid Phase Synthesis, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 22.3.3. Chemical Synthesis Market for Hybrid Phase Synthesis, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
22.4. Data Triangulation and Validation

23. PEPTIDE API CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION

23.1. Chapter Overview
23.2. Key Assumptions and Methodology
23.3. Peptide API Contract Manufacturing Market: Distribution by Scale of Operation
- 23.3.1. Peptide API Contract Manufacturing Market for Commercial Scale, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 23.3.2. Peptide API Contract Manufacturing Market for Preclinical / Clinical Scale, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
23.4. Data Triangulation and Validation

24. PEPTIDE API CONTRACT MANUFACTURING MARKET, BY COMPANY SIZE

24.1. Chapter Overview
24.2. Key Assumptions and Methodology
24.3. Peptide API Contract Manufacturing Market: Distribution by Company Size
- 24.3.1. Peptide API Contract Manufacturing Market for Very Large and Large Companies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 24.3.2. Peptide API Contract Manufacturing Market for Mid-sized Companies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 24.3.3. Peptide API Contract Manufacturing Market for Small Companies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
24.4. Data Triangulation and Validation

25. PEPTIDE API CONTRACT MANUFACTURING MARKET, BY GEOGRAPHY

25.1. Chapter Overview
25.2. Assumptions and Methodology
25.3. Peptide API Contract Manufacturing Market: Distribution by Geography
- 25.3.1. Peptide API Contract Manufacturing Market in North America, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  - 25.3.1.1. Peptide API Contract Manufacturing Market in the US, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  - 25.3.1.2. Peptide API Contract Manufacturing Market in Canada, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 25.3.2. Peptide API Contract Manufacturing Market in Europe, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  - 25.3.2.1. Peptide API Contract Manufacturing Market in Belgium, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  - 25.3.2.2. Peptide API Contract Manufacturing Market in Switzerland, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  - 25.3.2.3. Peptide API Contract Manufacturing Market in the UK, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  - 25.3.2.4. Peptide API Contract Manufacturing Market in Germany, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  - 25.3.2.5. Peptide API Contract Manufacturing Market in Ireland, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  - 25.3.2.6. Peptide API Contract Manufacturing Market in the Netherlands, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  - 25.3.2.7. Peptide API Contract Manufacturing Market in Italy, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  - 25.3.2.8. Peptide API Contract Manufacturing Market in France, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  - 25.3.2.9. Peptide API Contract Manufacturing Market in Sweden, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  - 25.3.2.10. Peptide API Contract Manufacturing Market in Rest of Europe, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 25.3.3. Peptide API Contract Manufacturing Market in Asia-Pacific and Rest of the World, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  - 25.3.3.1. Peptide API Contract Manufacturing Market in China, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  - 25.3.3.2. Peptide API Contract Manufacturing Market in India, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  - 25.3.3.3. Peptide API Contract Manufacturing Market in Japan, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  - 25.3.3.4. Peptide API Contract Manufacturing Market in Korea, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  - 25.3.3.5. Peptide API Contract Manufacturing Market in Other Countries, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
25.4. Market Movement Analysis
- 25.4.1. Penetration-Growth (P-G) Matrix
25.5. Data Triangulation and Validation

MARKET OPPORTUNITY ANALYSIS WITHIN GEOGRAPHY

26. MARKET OPPORTUNITY ANALYSIS: NORTH AMERICA

26.1. Peptide API Contract Manufacturing Market in North America: Distribution by Type of API
- 26.1.1. Peptide API Contract Manufacturing Market in North America for Generic APIs, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 26.1.2. Peptide API Contract Manufacturing Market in North America for New Chemical Entities, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
26.2. Peptide API Contract Manufacturing Market in North America: Distribution by Type of Peptide Synthesis Method
- 26.2.1. Peptide API Contract Manufacturing Market in North America for Chemical Synthesis, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 26.2.2. Peptide API Contract Manufacturing Market in North America for Non-chemical Synthesis, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
26.3. Peptide API Contract Manufacturing Market in North America: Distribution by Type of Chemical Synthesis Method
- 26.3.1. Chemical Synthesis Market in North America for Solid Phase Synthesis, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 26.3.2. Chemical Synthesis Market in North America for Liquid Phase Synthesis, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 26.3.3. Chemical Synthesis Market in North America for Hybrid Phase Synthesis, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
26.4. Peptide API Contract Manufacturing Market in North America: Distribution by Scale of Operation
- 26.4.1. Peptide API Contract Manufacturing Market in North America for Commercial Scale, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 26.4.2. Peptide API Contract Manufacturing Market in North America for Preclinical / Clinical Scale, Historical Trends (since 2021) and Forecasted Estimates
26.5. Peptide API Contract Manufacturing Market in North America: Distribution by Company Size
- 26.5.1. Peptide API Contract Manufacturing Market in North America for Very Large and Large Companies, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 26.5.2. Peptide API Contract Manufacturing Market in North America for Mid-sized Companies, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 26.5.3. Peptide API Contract Manufacturing Market in North America for Small Companies, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

27. MARKET OPPORTUNITY ANALYSIS: EUROPE

27.1. Peptide API Contract Manufacturing Market in Europe: Distribution by Type of API
- 27.1.1. Peptide API Contract Manufacturing Market in Europe for Generic APIs, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 27.1.2. Peptide API Contract Manufacturing Market in Europe for New Chemical Entities, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
27.2. Peptide API Contract Manufacturing Market in Europe: Distribution by Type of Peptide Synthesis Method
- 27.2.1. Peptide API Contract Manufacturing Market in Europe for Chemical Synthesis, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 27.2.2. Peptide API Contract Manufacturing Market in Europe for Non-chemical Synthesis, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
27.3. Peptide API Contract Manufacturing Market in Europe: Distribution by Type of Chemical Synthesis Method
- 27.3.1. Chemical Synthesis Market in Europe for Solid Phase Synthesis, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 27.3.2. Chemical Synthesis Market in Europe for Liquid Phase Synthesis, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 27.3.3. Chemical Synthesis Market in Europe for Hybrid Phase Synthesis, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
27.4. Peptide API Contract Manufacturing Market in Europe: Distribution by Scale of Operation
- 27.4.1. Peptide API Contract Manufacturing Market in Europe for Commercial Scale, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 27.4.2. Peptide API Contract Manufacturing Market in Europe for Preclinical / Clinical Scale, Historical Trends (since 2021) and Forecasted Estimates
27.5. Peptide API Contract Manufacturing Market in Europe: Distribution by Company Size
- 27.5.1. Peptide API Contract Manufacturing Market in Europe for Very Large and Large Companies, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 27.5.2. Peptide API Contract Manufacturing Market in Europe for Mid-sized Companies, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 27.5.3. Peptide API Contract Manufacturing Market in Europe for Small Companies, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

28. MARKET OPPORTUNITY ANALYSIS: ASIA-PACIFIC AND REST OF THE WORLD

28.1. Peptide API Contract Manufacturing Market in Asia-Pacific and Rest of the World: Distribution by Type of API
- 28.1.1. Peptide API Contract Manufacturing Market in Asia-Pacific and Rest of the World for Generic APIs, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 28.1.2. Peptide API Contract Manufacturing Market in Asia-Pacific and Rest of the World for New Chemical Entities, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
28.2. Peptide API Contract Manufacturing Market in Asia-Pacific and Rest of the World: Distribution by Type of Peptide Synthesis Method
- 28.2.1. Peptide API Contract Manufacturing Market in Asia-Pacific and Rest of the World for Chemical Synthesis, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 28.2.2. Peptide API Contract Manufacturing Market in Asia-Pacific and Rest of the World for Non-chemical Synthesis, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
28.3. Peptide API Contract Manufacturing Market in Asia-Pacific and Rest of the World: Distribution by Type of Chemical Synthesis Method
- 28.3.1. Chemical Synthesis Market in Asia-Pacific and Rest of the World for Solid Phase Synthesis, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 28.3.2. Chemical Synthesis Market in Asia-Pacific and Rest of the World for Liquid Phase Synthesis, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 28.3.3. Chemical Synthesis Market in Asia-Pacific and Rest of the World for Hybrid Phase Synthesis, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
28.4. Peptide API Contract Manufacturing Market in Asia-Pacific and Rest of the World: Distribution by Scale of Operation
- 28.4.1. Peptide API Contract Manufacturing Market in Asia-Pacific and Rest of the World for Commercial Scale, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 28.4.2.Peptide API Contract Manufacturing Market in Asia-Pacific and Rest of the World for Preclinical/Clinical Scale, Historical Trends (since2021) and Forecasted Estimates
28.5. Peptide API Contract Manufacturing Marketin Asia-Pacific and Rest of the World: Distribution by Company Size
- 28.5.1. Peptide API Contract Manufacturing Market in Asia-Pacific and Rest of the World for Very Largeand Large Companies, Historical Trends (since2021) and Forecasted Estimates (till2035)
- 28.5.2. Peptide API Contract Manufacturing Market in Asia-Pacific and Rest of the World for Mid-sized Companies, Historical Trends (since2021) and Forecasted Estimates (till2035)
- 28.5.3. Peptide API Contract Manufacturing Market in Asia-Pacific and Rest of the World for Small Companies, Historical Trends (since2021) and Forecasted Estimates (till2035)

29. SWOTANALYSIS

29.1. ChapterOverview
29.2. Strengths
29.3. Weaknesses
29.4. Opportunities
29.5. Threats
29.6. Comparison of SWOT Factors

30. ROOTS STRATEGIC RECOMMENDATIONS

31. INSIGHTS FROM PRIMARY RESEARCH

32. REPORT CONCLUSION

33. TABULATED DATA

34. LIST OF COMPANIES AND ORGANIZATIONS

35. CUSTOMIZATION OPPORTUNITIES

36. ROOTS SUBSCRIPTION SERVICES

簡介目錄圖表

List of Tables

Table 1.1 Peptide API Contract Manufacturing Market: Report Attributes / Market Segmentations
Table 6.1 Comparison of Major Peptide Synthesizing Processes
Table 6.2 Chromatographic Techniques
Table 7.1 Comparison of Regulatory Landscape of China and India
Table 8.1 Peptide API Contract Manufacturers: List of Companies
Table 8.2 Peptide API Contract Manufacturers: Information on Type of API Manufactured and Scale of Operation
Table 8.3 Peptide API Contract Manufacturers: Information on Type of Service Offered and Peptide Synthesis Method Used
Table 8.4 Peptide API Contract Manufacturers: Information on Type of Peptide Modification Offered and Type of Purification Technology Used
Table 8.5 Peptide API Contract Manufacturers: Information on Regulatory Certifications and Accreditations
Table 8.6 List of Custom Peptide Manufacturers
Table 10.1 Peptide API Contract Manufacturers: List of Companies Profiled
Table 10.2 AmbioPharm: Company Overview
Table 10.3 AmbioPharm: Peptide Synthesis Service Portfolio
Table 10.4 AmbioPharm: Peptide API Manufacturing Facilities and Capabilities
Table 10.5 AmbioPharm: Recent Developments and Future Outlook
Table 10.6 Creative Peptides: Company Overview
Table 10.7 Creative Peptides: Peptide Synthesis Service Portfolio
Table 10.8 Creative Peptides: Peptide API Manufacturing Facilities and Capabilities
Table 10.9 CSBio: Company Overview
Table 10.10 CSBio: Peptide Synthesis Service Portfolio
Table 10.11 CSBio: Peptide API Manufacturing Facilities and Capabilities
Table 10.12 CSBio: Recent Developments and Future Outlook
Table 10.13 Bachem: Company Overview
Table 10.14 Bachem: Peptide API Manufacturing Facilities and Capabilities
Table 10.15 Bachem: Peptide API Manufacturing Facilities and Capabilities
Table 10.16 Bachem: Recent Developments and Future Outlook
Table 10.17 BCN Peptides: Company Overview
Table 10.18 BCN Peptides: Peptide Synthesis Service Portfolio
Table 10.19 BCN Peptides: Peptide API Manufacturing Facilities and Capabilities
Table 10.20 BCN Peptides: Recent Developments and Future Outlook
Table 10.21 CordenPharma: Company Overview
Table 10.22 CordenPharma: Peptide Synthesis Service Portfolio
Table 10.23 CordenPharma: Peptide API Manufacturing Facilities and Capabilities
Table 10.24 CordenPharma: Recent Developments and Future Outlook
Table 10.25 PolyPeptide: Company Overview
Table 10.26 PolyPeptide: Peptide Synthesis Service Portfolio
Table 10.27 PolyPeptide: Peptide API Manufacturing Facilities and Capabilities
Table 10.28 PolyPeptide: Recent Developments and Future Outlook
Table 10.29 Senn Chemicals: Company Overview
Table 10.30 Senn Chemicals: Peptide Synthesis Service Portfolio
Table 10.31 Senn Chemicals: Peptide API Manufacturing Facilities and Capabilities
Table 10.32 Auspep: Company Overview
Table 10.33 Auspep: Peptide Synthesis Service Portfolio
Table 10.34 Auspep: Peptide API Manufacturing Facilities and Capabilities
Table 10.35 Hybio Pharmaceuticals: Company Overview
Table 10.36 Hybio Pharmaceuticals: Peptide Synthesis Service Portfolio
Table 10.37 Hybio Pharmaceuticals: Peptide API Manufacturing Facilities and Capabilities
Table 10.38 Hybio Pharmaceuticals: Recent Developments and Future Outlook
Table 10.39 Peptide Institute: Company Overview
Table 10.40 Peptide Institute: Peptide Synthesis Service Portfolio
Table 10.41 Peptide Institute: Peptide API Manufacturing Facilities and Capabilities
Table 10.42 ScinoPharm: Company Overview
Table 10.43 ScinoPharm: Peptide Synthesis Service Portfolio
Table 10.44 ScinoPharm: Peptide API Manufacturing Facilities and Capabilities
Table 10.45 ScinoPharm: Recent Developments and Future Outlook
Table 11.1 Peptide API Contract Manufacturers: List of Partnerships and Collaborations, Since 2021
Table 11.2 Partnerships and Collaborations: Information on Type of Agreement (Country-wise and Region-wise)
Table 11.3 Peptide API Contract Manufacturers: List of Recent Expansions, Since 2021
Table 15.1 Peptide API Contract Manufacturers: Information on Total Installed Capacity (Sample Dataset)
Table 15.2 Peptide API Contract Manufacturing: Average Capacity based on Company Size (Sample Dataset)
Table 15.3 Peptide API Contract Manufacturing Capacity: Average Share Based on Synthesis Method (Sample Dataset)
Table 15.4 Global Installed Peptide API Contract Manufacturing Capacity: Distribution by Company Size (liters)
Table 16.1 Potential Strategic Partners for Peptide API Contract Manufacturers Based in North America
Table 16.2 Potential Strategic Partners for Peptide API Contract Manufacturers Based in Europe
Table 16.3 Potential Strategic Partners for Peptide API Contract Manufacturers Based in Asia-Pacific and Rest of the World
Table 29.1 Peptide API Contract Manufacturers: Distribution by Year of Establishment
Table 29.2 Peptide API Contract Manufacturers: Distribution by Year of Experience of Peptide API Contract Manufacturers
Table 29.3 Peptide API Contract Manufacturers: Distribution by Company Size
Table 29.4 Peptide API Contract Manufacturers: Distribution by Location of Headquarters
Table 29.5 Peptide API Contract Manufacturers: Distribution by Type of Product Manufactured
Table 29.6 Peptide API Contract Manufacturers: Distribution by Type of API Manufactured
Table 29.7 Peptide API Contract Manufacturers: Distribution by Scale of Operation
Table 29.8 Peptide API Contract Manufacturers: Distribution by Type of Service Offered
Table 29.9 Peptide API Contract Manufacturers: Distribution by Type of Peptide Synthesis Method Used
Table 29.10 Peptide API Contract Manufacturers: Distribution by Type of Peptide Modification Offered
Table 29.11 Peptide API Contract Manufacturers: Distribution by Type of Purification Technology Used
Table 29.12 Peptide API Contract Manufacturers: Distribution by Regulatory Certifications and Accreditations
Table 29.13 Peptide API Contract Manufacturers: Distribution by Geographical Presence
Table 29.14 Peptide API Contract Manufacturers: Distribution by Location of Peptide API Manufacturing Facilities (Region)
Table 29.15 Peptide API Contract Manufacturers: Distribution by Number of Peptide API Manufacturing Facilities (Country)
Table 29.16 Bachem: Financial Information, Since 2022 (CHF Million)
Table 29.17 PolyPeptide: Financial Information, Since 2022 (EUR Million)
Table 29.18 ScinoPharm: Financial Information, Since 2022 (NTD Billion)
Table 29.19 Partnerships and Collaborations: Cumulative Year-wise Trend, Since 2021
Table 29.20 Partnerships and Collaborations: Distribution by Type of Partnership
Table 29.21 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 29.22 Partnerships and Collaborations: Distribution by Company Size and Type of Partnership
Table 29.23 Partnerships and Collaborations: Distribution by Scale of Operation
Table 29.24 Partnerships and Collaborations: Distribution by Scale of Operation and Type of Partnership
Table 29.25 Partnerships and Collaborations: Distribution by Green Chemistry Integration
Table 29.26 Most Active Players: Distribution by Number of Partnerships
Table 29.27 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 29.28 Partnerships and Collaborations: Local and International Agreements
Table 29.29 Recent Expansions: Cumulative Year-wise Trend, Since 2021
Table 29.30 Recent Expansions: Distribution by Type of Expansion
Table 29.31 Recent Expansions: Distribution by Year and Type of Expansion
Table 29.32 Recent Expansions: Distribution by Location of Expanded Facility (Region)
Table 29.33 Recent Expansions: Distribution by Location of Expanded Facility (Country)
Table 29.34 Recent Expansions: Distribution by Location of Expanded Facility and Type of Expansion
Table 29.35 Most Active Players: Distribution by Number of Expansions
Table 29.36 Recent Expansions: Distribution by Geography (Country)
Table 29.37 Clinical Trial Analysis: Cumulative Year-wise Trend, Since 2021
Table 29.38 Clinical Trial Analysis: Number of Patients Enrolled by Trial Registration Year, Since 2021
Table 29.39 Clinical Trial Analysis: Distribution by Trial Phase
Table 29.40 Clinical Trial Analysis: Distribution of Trials by Trial Registration Year and Trial Phase, Since 2021
Table 29.41 Clinical Trial Analysis: Distribution by Number of Patients Enrolled by Trial Phase
Table 29.42 Clinical Trial Analysis: Distribution by Trial Status
Table 29.43 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, Since 2021
Table 29.44 Clinical Trial Analysis: Distribution by Therapeutic Area
Table 29.45 Clinical Trial Analysis: Distribution by Patient Gender
Table 29.46 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 29.47 Clinical Trial Analysis: Distribution by Type of Allocation
Table 29.48 Clinical Trial Analysis: Distribution by Type of Masking
Table 29.49 Clinical Trial Analysis: Distribution by Type of Intervention
Table 29.50 Clinical Trial Analysis: Distribution by Trial Purpose
Table 29.51 Leading Industry Players: Distribution by Number of Clinical Trials
Table 29.52 Clinical Trial Analysis: Distribution of Clinical Trials by Geography
Table 29.53 Clinical Trial Analysis: Distribution of Clinical Trials by Geography and Trial Status
Table 29.54 Clinical Trial Analysis: Distribution of Patients Enrolled by Geography
Table 29.55 Clinical Trial Analysis: Distribution of Patients Enrolled by Geography and Trial Status
Table 29.56 Regional Distribution of Peptide API Contract Manufacturing Facilities
Table 29.57 Regional Capability Analysis: Peptide API Contract Manufacturers in North America
Table 29.58 Regional Capability Analysis: Peptide API Contract Manufacturers in Europe
Table 29.59 Regional Capability Analysis: Peptide API Contract Manufacturers in Asia-Pacific and Rest of the World
Table 29.60 Global Demand for Peptide API Contract Manufacturing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (Kilograms)
Table 29.61 Global Clinical Demand for Peptide API Contract Manufacturing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (Kilograms)
Table 29.62 Clinical Demand for Peptide API Contract Manufacturing: Distribution by Phase of Development
Table 29.63 Clinical Demand for Peptide API Contract Manufacturing: Phase I Trials, Till 2035 (Kilograms)
Table 29.64 Clinical Demand for Peptide API Contract Manufacturing: Phase II Trials, Till 2035 (Kilograms)
Table 29.65 Clinical Demand for Peptide API Contract Manufacturing: Phase III Trials, Till 2035 (Kilograms)
Table 29.66 Global Commercial Demand for Peptide API Contract Manufacturing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (Kilograms)
Table 29.67 Commercial Demand for Peptide API Contract Manufacturing: Distribution by Mechanism of Action
Table 29.68 Commercial Demand for Peptide API Contract Manufacturing for GLP-1 Drugs, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (Kilograms)
Table 29.69 Commercial Demand for Peptide API Contract Manufacturing for non-GLP-1 Drugs, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (Kilograms)
Table 29.70 Global Demand for Peptide API Contract Manufacturing: Distribution by Type of Peptide Synthesis Method (Kilograms)
Table 29.71 Global Demand for Peptide API Contract Manufacturing: Distribution by Geographical Regions (Kilograms)
Table 29.72 Global Installed Peptide API Contract Manufacturing Capacity: Distribution by Company Size
Table 29.73 Global Installed Peptide API Contract Manufacturing Capacity: Distribution by Range of Installed Capacity (Liters)
Table 29.74 Global Installed Peptide API Contract Manufacturing Capacity: Distribution by Scale of Operation (Liters)
Table 29.75 Global Installed Peptide API Contract Manufacturing Capacity: Distribution by Location of Manufacturing Facility (Liters)
Table 29.76 Peptide API Contract Manufacturing Capacity in North America
Table 29.77 Peptide API Contract Manufacturing Capacity in Europe
Table 29.78 Peptide API Contract Manufacturing Capacity in Asia-Pacific and Rest of the World
Table 29.78 Global Installed Peptide API Contract Manufacturing Capacity: Distribution by Company Size and Location of Manufacturing Facility
Table 29.79 Global Installed Peptide API Contract Manufacturing Capacity: Distribution by Synthesis Method (Liters)
Table 29.80 Total Cost of Ownership of Peptide API Contract Manufacturing Organization, Y0-Y20 (USD Million)
Table 29.81 Total Cost of Ownership of Peptide API Contract Manufacturing Organization: Distribution by CAPEX and OPEX, Y0 and Y20 (USD Million)
Table 29.82 Total Cost of Ownership of Peptide API Contract Manufacturing Organization, Y0: Distribution by CAPEX (USD Million)
Table 29.83 Total Cost of Ownership of Peptide API Contract Manufacturing Organization, Y1-Y20: Distribution by OPEX (USD Million)
Table 29.84 Global Peptide API Contract Manufacturing Market, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 29.85 Global Peptide API Contract Manufacturing Market, Forecasted Estimates (Till 2035): Conservative Scenario (USD Billion)
Table 29.86 Global Peptide API Contract Manufacturing Market, Forecasted Estimates (Till 2035): Optimistic Scenario (USD Billion)
Table 29.87 Peptide API Contract Manufacturing Market: Distribution by Type of API
Table 29.88 Peptide API Contract Manufacturing Market for Generic APIs, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 29.89 Peptide API Contract Manufacturing Market for New Chemical Entities, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 29.90 Peptide API Contract Manufacturing Market: Distribution by Type of Peptide Synthesis Method
Table 29.91 Peptide API Contract Manufacturing Market for Chemical Synthesis, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 29.92 Peptide API Contract Manufacturing Market for Non-chemical Synthesis, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 29.93 Peptide API Contract Manufacturing Market: Distribution by Type of Chemical Synthesis Method
Table 29.94 Peptide API Contract Manufacturing Market for Solid Phase Synthesis, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 29.95 Peptide API Contract Manufacturing Market for Liquid Phase Synthesis, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 29.96 Peptide API Contract Manufacturing Market for Hybrid Phase Synthesis, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 29.97 Peptide API Contract Manufacturing Market: Distribution by Scale of Operation
Table 29.98 Peptide API Contract Manufacturing Market for Commercial Scale, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 29.99 Peptide API Contract Manufacturing Market for Preclinical / Clinical Scale, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 29.100 Peptide API Contract Manufacturing Market: Distribution by Company Size
Table 29.101 Peptide API Contract Manufacturing Market for Very Large and Large Companies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 29.102 Peptide API Contract Manufacturing Market for Mid-sized Companies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 29.103 Peptide API Contract Manufacturing Market for Small Companies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 29.104 Peptide API Contract Manufacturing Market: Distribution Geography
Table 29.105 Peptide API Contract Manufacturing Market in North America, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 29.106 Peptide API Contract Manufacturing Market in the US, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 29.107 Peptide API Contract Manufacturing Market in Canada, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 29.108 Peptide API Contract Manufacturing Market in Europe, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 29.109 Peptide API Contract Manufacturing Market in Belgium, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 29.110 Peptide API Contract Manufacturing Market in Switzerland, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 29.111 Peptide API Contract Manufacturing Market in the UK, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 29.112 Peptide API contract manufacturing market in Germany, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 29.113 Peptide API Contract Manufacturing Market in Ireland, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 29.114 Peptide API Contract Manufacturing Market in the Netherlands, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 29.115 Peptide API Contract Manufacturing Market in Italy, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 29.116 Peptide API Contract Manufacturing Market in France, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 29.117 Peptide API Contract Manufacturing Market in Sweden, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 29.118 Peptide API Contract Manufacturing Market in Rest of Europe, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 29.119 Peptide API Contract Manufacturing Market in Asia-Pacific and Rest of the World, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 29.120 Peptide API Contract Manufacturing Market in China, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 29.121 Peptide API Contract Manufacturing Market in India, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 29.122 Peptide API Contract Manufacturing Market in Japan, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 29.123 Peptide API Contract Manufacturing Market in Korea, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 29.124 Peptide API Contract Manufacturing Market in Other Countries, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)

List of Figures

Figure 2.1 Research Methodology: Project Methodology
Figure 2.2 Research Methodology: Data Sources for Secondary Research
Figure 2.3 Research Methodology: Robust Quality Control
Figure 3.1 Market Dynamics: Forecast Methodology
Figure 3.2 Market Dynamics: Market Assessment Framework
Figure 4.1 Lessons Learnt from Past Recessions
Figure 5.1 Executive Summary: Overall Market Landscape
Figure 5.2 Executive Summary: Recent Developments
Figure 5.3 Executive Summary: Clinical Trial Analysis
Figure 5.4 Executive Summary: Demand Analysis
Figure 5.5 Executive Summary: Capacity Analysis
Figure 5.6 Executive Summary: Market Forecast and Opportunity Analysis
Figure 6.1 Methods of Peptide Synthesis
Figure 6.2 Latest Technologies for Peptide Synthesis
Figure 6.3 Peptide Modification Techniques
Figure 6.4 Types of Third-Party Service Providers
Figure 7.1 Regulatory Agencies Governing Peptide Manufacturing in the US
Figure 8.1 Peptide API Contract Manufacturers: Distribution by Year of Establishment
Figure 8.2 Peptide API Contract Manufacturers: Distribution by Year of Experience of Peptide API Contract Manufacturers
Figure 8.3 Peptide API Contract Manufacturers: Distribution by Company Size
Figure 8.4 Peptide API Contract Manufacturers: Distribution by Location of Headquarters
Figure 8.5 Peptide API Contract Manufacturers: Distribution by Type of Product Manufactured
Figure 8.6 Peptide API Contract Manufacturers: Distribution by Type of API Manufactured
Figure 8.7 Peptide API Contract Manufacturers: Distribution by Scale of Operation
Figure 8.8 Peptide API Contract Manufacturers: Distribution by Type of Service Offered
Figure 8.9 Peptide API Contract Manufacturers: Distribution by Type of Peptide Synthesis Method Used
Figure 8.10 Peptide API Contract Manufacturers: Distribution by Type of Peptide Modification Offered
Figure 8.11 Peptide API Contract Manufacturers: Distribution by Type of Purification Technology Used
Figure 8.12 Peptide API Contract Manufacturers: Distribution by Regulatory Certifications and Accreditations
Figure 8.13 Peptide API Contract Manufacturers: Distribution by Geographical Presence
Figure 8.14 Peptide API Contract Manufacturers: Distribution by Location of Peptide API Manufacturing Facilities (Region)
Figure 8.15 Peptide API Contract Manufacturers: Distribution by Number of Peptide API Manufacturing Facilities (Country)
Figure 9.1 Company Competitiveness Analysis: Peptide API Contract Manufacturers Headquartered in North America
Figure 9.2 Company Competitiveness Analysis: Peptide API Contract Manufacturers Headquartered in Europe
Figure 9.3 Company Competitiveness Analysis: Peptide API Contract Manufacturers Headquartered in Asia-Pacific and Rest of the World
Figure 10.1 Bachem: Financial Information, Since 2022 (CHF Million)
Figure 10.2 PolyPeptide: Financial Information, Since 2022 (EUR Million)
Figure 10.3 ScinoPharm: Financial Information, Since 2022 (NTD Billion)
Figure 10.4 Amneal Pharmaceuticals: Company Details
Figure 10.5 Amneal Pharmaceuticals: Financial Details
Figure 10.6 Amneal Pharmaceuticals: SWOT Analysis
Figure 10.7 Amneal Pharmaceuticals: Strategic Framework
Figure 10.8 Amneal Pharmaceuticals: Recent Developments and Future Outlook
Figure 10.9 Asymchem: Company Details
Figure 10.10 Asymchem: Peptide Synthesis Service Portfolio
Figure 10.11 Asymchem: Peptide Synthesis Facilities
Figure 10.12 Asymchem: Financial Details
Figure 10.13 Asymchem: SWOT Analysis
Figure 10.14 Asymchem: Strategic Framework
Figure 10.15 Asymchem: Recent Developments and Future Outlook
Figure 10.16 Aurisco Pharma: Company Details
Figure 10.17 Aurisco Pharma: Peptide Synthesis Facilities
Figure 10.18 Aurisco Pharma: Financial Details
Figure 10.19 Aurisco Pharma: SWOT Analysis
Figure 10.20 Aurisco Pharma: Strategic Framework
Figure 10.21 Aurisco Pharma: Recent Developments and Future Outlook
Figure 10.22 Dr Reddy's Laboratories: Company Details
Figure 10.23 Dr Reddy's Laboratories: Peptide Synthesis Service Portfolio
Figure 10.24 Dr Reddy's Laboratories: Peptide Synthesis Facilities
Figure 10.25 Dr Reddy's Laboratories: Financial Details
Figure 10.26 Dr Reddy's Laboratories: SWOT Analysis
Figure 10.27 Dr Reddy's Laboratories: Strategic Framework
Figure 10.28 Dr Reddy's Laboratories: Recent Developments and Future Outlook
Figure 10.29 Hybio Pharmaceutical: Company Details
Figure 10.30 Hybio Pharmaceutical: Peptide Synthesis Service Portfolio
Figure 10.31 Hybio Pharmaceutical: Peptide Synthesis Facilities
Figure 10.32 Hybio Pharmaceutical: SWOT Analysis
Figure 10.33 Hybio Pharmaceutical: Strategic Framework
Figure 10.34 Hybio Pharmaceutical: Recent Developments and Future Outlook
Figure 10.35 JYMed Peptide: Company Details
Figure 10.36 JYMed Peptide: Peptide Synthesis Service Portfolio
Figure 10.37 JYMed Peptide: Peptide Synthesis Facilities
Figure 10.38 JYMed Peptide: SWOT Analysis
Figure 10.39 JYMed Peptide: Strategic Framework
Figure 10.40 JYMed Peptide: Recent Developments and Future Outlook
Figure 10.41 Neuland Labs: Company Details
Figure 10.42 Neuland Labs: Peptide Synthesis Service Portfolio
Figure 10.43 Neuland Labs: Peptide Synthesis Facilities
Figure 10.44 Neuland Labs: Financial Details
Figure 10.45 Neuland Labs: SWOT Analysis
Figure 10.46 Neuland Labs: Strategic Framework
Figure 10.47 Neuland Labs: Recent Developments and Future Outlook
Figure 10.48 Sinopep-Allsino Biopharmaceutical: Company Details
Figure 10.49 Sinopep-Allsino Biopharmaceutical: Peptide Synthesis Service Portfolio
Figure 10.50 Sinopep-Allsino Biopharmaceutical: Peptide Synthesis Facilities
Figure 10.51 Sinopep-Allsino Biopharmaceutical: Financial Details
Figure 10.52 Sinopep-Allsino Biopharmaceutical: SWOT Analysis
Figure 10.53 Sinopep-Allsino Biopharmaceutical: Strategic Framework
Figure 10.54 Sinopep-Allsino Biopharmaceutical: Recent Developments and Future Outlook
Figure 10.55 SK Pharmteco: Company Details
Figure 10.56 SK Pharmteco: Financial Details
Figure 10.57 SK Pharmteco: SWOT Analysis
Figure 10.58 SK Pharmteco: Strategic Framework
Figure 10.59 SK Pharmteco: Recent Developments and Future Outlook
Figure 10.60 WuXi STA (a WuXi AppTec company): Company Details
Figure 10.61 WuXi STA (a WuXi AppTec company): Peptide Synthesis Service Portfolio
Figure 10.62 WuXi STA (a WuXi AppTec company): Peptide Synthesis Facilities
Figure 10.63 WuXi STA (a WuXi AppTec company): Financial Details
Figure 10.64 WuXi STA (a WuXi AppTec company): SWOT Analysis
Figure 10.65 WuXi STA (a WuXi AppTec company): Strategic Framework
Figure 10.66 WuXi STA (a WuXi AppTec company): Recent Developments and Future Outlook
Figure 11.1 Partnerships and Collaborations: Cumulative Year-wise Trend, Since 2021
Figure 11.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 11.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 11.4 Partnerships and Collaborations: Distribution by Company Size and Type of Partnership
Figure 11.5 Partnerships and Collaborations: Distribution by Scale of Operation
Figure 11.6 Partnerships and Collaborations: Distribution by Scale of Operation and Type of Partnership
Figure 11.7 Partnerships and Collaborations: Distribution by Green Chemistry Integration
Figure 11.8 Most Active Players: Distribution by Number of Partnerships
Figure 11.9 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 11.10 Partnerships and Collaborations: Local and International Agreements
Figure 11.11 Recent Expansions: Cumulative Year-wise Trend, Since 2021
Figure 11.12 Recent Expansions: Distribution by Type of Expansion
Figure 11.13 Recent Expansions: Distribution by Year and Type of Expansion
Figure 11.14 Recent Expansions: Distribution by Location of Expanded Facility (Region)
Figure 11.15 Recent Expansions: Distribution by Location of Expanded Facility (Country)
Figure 11.16 Recent Expansions: Distribution by Location of Expanded Facility and Type of Expansion
Figure 11.17 Most Active Players: Distribution by Number of Expansions
Figure 11.18 Recent Expansions: Distribution by Geography (Country)
Figure 11.19 Chemo-Enzymatic Peptide Synthesis Technology: Advantages and Disadvantages
Figure 11.20 Continuous Flow Technology: Advantages and Disadvantages
Figure 11.21 Green Chemistry: Advantages and Disadvantages
Figure 12.1 Clinical Trial Analysis: Scope and Methodology
Figure 12.2 Clinical Trial Analysis: Cumulative Year-wise Trend, Since 2021
Figure 12.3 Clinical Trial Analysis: Number of Patients Enrolled by Trial Registration Year, Since 2021
Figure 12.4 Clinical Trial Analysis: Distribution by Trial Phase
Figure 12.5 Clinical Trial Analysis: Distribution of Trials by Trial Registration Year and Trial Phase, Since 2021
Figure 12.6 Clinical Trial Analysis: Distribution by Number of Patients Enrolled by Trial Phase
Figure 12.7 Clinical Trial Analysis: Distribution by Trial Status
Figure 12.8 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, Since 2021
Figure 12.9 Clinical Trial Analysis: Distribution by Therapeutic Area
Figure 12.10 Clinical Trial Analysis: Distribution by Patient Gender
Figure 12.11 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 12.12 Clinical Trial Analysis: Distribution by Type of Allocation
Figure 12.13 Clinical Trial Analysis: Distribution by Type of Masking
Figure 12.14 Clinical Trial Analysis: Distribution by Type of Intervention
Figure 12.15 Clinical Trial Analysis: Distribution by Trial Purpose
Figure 12.16 Leading Industry Players: Distribution by Number of Clinical Trials
Figure 12.17 Clinical Trial Analysis: Distribution of Clinical Trials by Geography
Figure 12.18 Clinical Trial Analysis: Distribution of Clinical Trials by Geography and Trial Status
Figure 12.19 Clinical Trial Analysis: Distribution of Patients Enrolled by Geography
Figure 12.20 Clinical Trial Analysis: Distribution of Patients Enrolled by Geography and Trial Status
Figure 13.1 Regional Distribution of Peptide API Contract Manufacturing Facilities
Figure 13.2 Regional Capability Analysis: Peptide API Contract Manufacturers in North America
Figure 13.3 Regional Capability Analysis: Peptide API Contract Manufacturers in Europe
Figure 13.4 Regional Capability Analysis: Peptide API Contract Manufacturers in Asia-Pacific and Rest of the World
Figure 14.1 Global Demand for Peptide API Contract Manufacturing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (Kilograms)
Figure 14.2 Global Clinical Demand for Peptide API Contract Manufacturing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (Kilograms)
Figure 14.3 Clinical Demand for Peptide API Contract Manufacturing: Distribution by Phase of Development
Figure 14.4 Clinical Demand for Peptide API Contract Manufacturing: Phase I Trials, Till 2035 (Kilograms)
Figure 14.5 Clinical Demand for Peptide API Contract Manufacturing: Phase II Trials, Till 2035 (Kilograms)
Figure 14.6 Clinical Demand for Peptide API Contract Manufacturing: Phase III Trials, Till 2035 (Kilograms)
Figure 14.7 Global Commercial Demand for Peptide API Contract Manufacturing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (Kilograms)
Figure 14.8 Commercial Demand for Peptide API Contract Manufacturing: Distribution by Mechanism of Action
Figure 14.9 Commercial Demand for Peptide API Contract Manufacturing for GLP-1 Drugs, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (Kilograms)
Figure 14.10 Commercial Demand for Peptide API Contract Manufacturing for non-GLP-1 Drugs, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (Kilograms)
Figure 14.11 Global Demand for Peptide API Contract Manufacturing: Distribution by Type of Peptide Synthesis Method (Kilograms)
Figure 14.12 Global Demand for Peptide API Contract Manufacturing: Distribution by Geographical Regions (Kilograms)
Figure 15.1 Global Installed Peptide API Contract Manufacturing Capacity: Distribution by Company Size
Figure 15.2 Global Installed Peptide API Contract Manufacturing Capacity: Distribution by Range of Installed Capacity (Liters)
Figure 15.3 Global Installed Peptide API Contract Manufacturing Capacity: Distribution by Scale of Operation (Liters)
Figure 15.4 Global Installed Peptide API Contract Manufacturing Capacity: Distribution by Location of Manufacturing Facility (Liters)
Figure 15.5 Peptide API Contract Manufacturing Capacity in North America
Figure 15.6 Peptide API Contract Manufacturing Capacity in Europe
Figure 15.7 Peptide API Contract Manufacturing Capacity in Asia-Pacific and Rest of the World
Figure 15.7 Global Installed Peptide API Contract Manufacturing Capacity: Distribution by Company Size and Location of Manufacturing Facility
Figure 15.8 Global Installed Peptide API Contract Manufacturing Capacity: Distribution by Synthesis Method (Liters)
Figure 16.1 Spider-web Analysis: Potential Strategic Partners
Figure 17.1 Make versus Buy Decision Making Framework
Figure 17.2 Make versus Buy Decision Making: Possible Scenario
Figure 18.1 Total Cost of Ownership: Capital Expenditures (CAPEX)
Figure 18.2 Total Cost of Ownership: Operational Expenditures (OPEX)
Figure 18.3 Total Cost of Ownership of Peptide API Contract Manufacturing Organization, Y0-Y20 (USD Million)
Figure 18.4 Total Cost of Ownership of Peptide API Contract Manufacturing Organization: Distribution by CAPEX and OPEX, Y0 and Y20 (USD Million)
Figure 18.5 Total Cost of Ownership of Peptide API Contract Manufacturing Organization, Y0: Distribution by CAPEX (USD Million)
Figure 18.6 Total Cost of Ownership of Peptide API Contract Manufacturing Organization, Y1-Y20: Distribution by OPEX (USD Million)
Figure 19.1 Global Peptide API Contract Manufacturing Market, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 19.2 Global Peptide API Contract Manufacturing Market, Forecasted Estimates (Till 2035): Conservative Scenario (USD Billion)
Figure 19.3 Global Peptide API Contract Manufacturing Market, Forecasted Estimates (Till 2035): Optimistic Scenario (USD Billion)
Figure 20.1 Peptide API Contract Manufacturing Market: Distribution by Type of API
Figure 20.2 Peptide API Contract Manufacturing Market for Generic APIs, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 20.3 Peptide API Contract Manufacturing Market for New Chemical Entities, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 21.1 Peptide API Contract Manufacturing Market: Distribution by Type of Peptide Synthesis Method
Figure 21.2 Peptide API Contract Manufacturing Market for Chemical Synthesis, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 21.3 Peptide API Contract Manufacturing Market for Non-chemical Synthesis, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 22.1 Peptide API Contract Manufacturing Market: Distribution by Type of Chemical Synthesis Method
Figure 22.2 Peptide API Contract Manufacturing Market for Solid Phase Synthesis, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 22.3 Peptide API Contract Manufacturing Market for Liquid Phase Synthesis, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 22.4 Peptide API Contract Manufacturing Market for Hybrid Phase Synthesis, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 23.1 Peptide API Contract Manufacturing Market: Distribution by Scale of Operation
Figure 23.2 Peptide API Contract Manufacturing Market for Commercial Scale, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 23.3 Peptide API Contract Manufacturing Market for Preclinical / Clinical Scale, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 24.1 Peptide API Contract Manufacturing Market: Distribution by Company Size
Figure 24.2 Peptide API Contract Manufacturing Market for Very Large and Large Companies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 24.3 Peptide API Contract Manufacturing Market for Mid-sized Companies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 24.4 Peptide API Contract Manufacturing Market for Small Companies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 25.1 Peptide API Contract Manufacturing Market: Distribution Geography
Figure 25.2 Peptide API Contract Manufacturing Market in North America, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 25.3 Peptide API Contract Manufacturing Market in the US, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 25.4 Peptide API Contract Manufacturing Market in Canada, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 25.5 Peptide API Contract Manufacturing Market in Europe, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 25.6 Peptide API Contract Manufacturing Market in Belgium, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 25.7 Peptide API Contract Manufacturing Market in Switzerland, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 25.8 Peptide API Contract Manufacturing Market in the UK, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 25.9 Peptide API Contract Manufacturing Market in Germany, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 25.10 Peptide API Contract Manufacturing Market in Ireland, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 25.11 Peptide API Contract Manufacturing Market in the Netherlands, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 25.12 Peptide API Contract Manufacturing Market in Italy, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 25.13 Peptide API Contract Manufacturing Market in France, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 25.14 Peptide API Contract Manufacturing Market in Sweden, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 25.15 Peptide API Contract Manufacturing Market in Rest of Europe, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 25.16 Peptide API Contract Manufacturing Market in Asia-Pacific and Rest of the World, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 25.17 Peptide API Contract Manufacturing Market in China, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 25.18 Peptide API Contract Manufacturing Market in India, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 25.19 Peptide API Contract Manufacturing Market in Japan, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 25.20 Peptide API Contract Manufacturing Market in Korea, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 25.21 Peptide API Contract Manufacturing Market in Other Countries, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 25.22 Market Movement Analysis: Geography
Figure 25.23 Penetration-Growth (P-G) Matrix: Geography
Figure 26.1 Contract Peptide API Manufacturing: SWOT Analysis
Figure 26.2 Comparison of SWOT Factors: Harvey Ball Analysis
Figure 27.1 Concluding Remarks: Overall Market Landscape (I/II)
Figure 27.2 Concluding Remarks: Overall Market Landscape (I/II)
Figure 27.3 Concluding Remarks: Recent Developments (I/II)
Figure 27.4 Concluding Remarks: Recent Developments (I/II)
Figure 27.5 Concluding Remarks: Clinical Trial Analysis
Figure 27.6 Concluding Remarks: Demand Analysis
Figure 27.7 Concluding Remarks: Capacity Analysis
Figure 27.8 Concluding Remarks: Market Sizing and Opportunity Analysis (I/II)
Figure 27.9 Concluding Remarks: Market Sizing and Opportunity Analysis (II/II)